Atty. Docket No.: INGA, 004/CIP Information Disclosure Statement IDS filed: May 30, 2006

NITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of:

CONRAD

Group Art Unit:

1633

Serial No:

09/397,782

Examiner:

J. Martinell

Filed:

Sept. 16, 1999

Atty. Docket No:

INGA,004/CIP

Title:

IN VIVO PRODUCTION OF SSDNA USING REVERSE TRANSCRIPTASE WITH PREDEFINED REACTION TERMINATION VIA STEM-LOOP FORMATION

TO:

Commissioner of Patents and Trademarks PO Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING (37 CFR 1.8a) I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope, addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with Applicant's duty of candor and good faith, Applicant files this Information Disclosure Statement in accordance with the provisions of 37 CFR §§1.97 and 1.98 to make the references listed on the attached disclosure form PTO/SB/08 of record in the captioned application.

Also, in compliance with § 1.97, an information disclosure statement is herein filed within one of the following time periods:

☑ (1) the information disclosure statement is filed in the early stages of prosecution:

within three months of the filing date of a national application other than a continued
prosecution application under §1.53(d);

- within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- □ before the mailing of a first Office action on the merits; OR
- before the mailing of a first Office action after the filing of a request for continued examination under §1.114;

Atty. Docket No.: INGA, 004/CIP Information Disclosure Statement IDS filed: May 30, 2006

OR, (2) the information disclosure statement is filed before the mailing date of any of a final action under \$1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and it is accompanied by ONE OF: ☐ A statement as specified under 37 CFR 1.97(e): ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; OR That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement. OR, \square The fee set forth in §1.17(p), OR, (3) the information disclosure statement is filed on or before payment of the issue fee and is accompanied by: ☐ The statement specified under 37 CFR 1.97(e); ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement: OR That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. AND, \square The fee set forth in §1.17(p).

Atty. Docket No.: INGA, 004/CIP Information Disclosure Statement IDS filed: May 30, 2006

Also, in accordance with the above provisions, please find:

A copy of an earlier filed Information Disclosure Statement from a related but earlier filed application containing similar subject matter which may be material to the patentability of this continuation, divisional or continuation-in-part application.

The earlier filed information disclosure statement was submitted for application:

SN 08/236,504	IDS filed June 3, 1996 (INGA,002)
SN 09/169,793	IDS filed Oct. 18, 2000 (INGA,004)
SN 09/169,793	Supplemental IDS filed May 17, 2006 (INGA,004)
SN 09/169,793	2 nd Supp. IDS filed May 30, 2006 (INGA,004)

Applicant hereby requests consideration of the art previously cited on the copies provided.

A copy of search reports provided by official examining authorities for applications containing similar subject matter which may be material to the patentability of this application.

The search reports were generated for applications:

PCT/US99/23936	Filed Oct. 12, 1999	(INGA,004/PCT)
PCT/US00/27381	Filed Oct. 4, 2000	(INGA,004/CIP/PCT)
PCT/US99/23933	Filed Oct. 12, 1999	(CRYA,008/PCT)
PCT/US03/13593	Filed Oct. 21, 2003	(CRYA,018/PCT)
PCT/US03/39033	Filed Sept. 8, 2004	(CRYA,023/PCT)
SN 09/397,783	Filed Sept. 16, 1999	(CRYA,008)
SN 10/136,218	Filed May 1, 2002	(CRYA,018)
SN 10/313,828	Filed Dec. 6, 2002	(CRYA,023)
SN 10/453,410	Filed June 3, 2003	(CRYA,025)
SN 10/818,158	Filed April 5, 2004	(CRYA,025/C/CIP)
Written Opinion	PCT/US99/23936	(INGA,004/PCT)
Written Opinion	PCT/US00/27381	(INGA,004/CIP/PCT)
Written Opinion	PCT/US99/23933	(CRYA,008/PCT)
Examination Report	EP 99 950 296.6	(INGA,004/PCT)

Applicant hereby requests consideration of the art cited on the copies provided.

- ☑ An Information Disclosure Statement in accordance with §1.98(a)(1);
- ☑ Legible Copies in accordance with §1.98(a)(2) of:
 - (i) each foreign patent;
 - (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office;
 - (iii) for each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and
 - (iv) all other information or that portion which caused it to be listed.

∟ i	In accordance with §1.98(a)(3), for documents not in the English language:
	☐ a concise explanation of the relevance, as it is presently understood by the individual
	designated in §1.56(c) most knowledgeable about the content of the information, of each
	patent, publication, or other information listed that is not in the English language;

Atty. Docket No.: INGA, 004/CIP Information Disclosure Statement IDS filed: May 30, 2006

AND,

a copy of the translation if a written English-language translation of a non-English-
language document, or portion thereof, is within the possession, custody, or control of, or
is readily available to any individual designated in §1.56(c).

- ☐ A Check in the amount of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §§1.97(c)(2) and 1.97(d)(2).
- A Revocation of Power of Attorney with New Power of Attorney and Change of Correspondence Address with New Power of Attorney and Change of Correspondence Address
- A copy of Statement under 37 CFR 3.73(b) and any required accompanying documents.
- A stamped, self-addressed Postcard acknowledging receipt of this document and the accompanying documents as listed herein above.

Please return the enclosed postcard, properly date stamped, to the undersigned attorney for Applicant upon receipt of the enclosed correspondence.

In the event a check covering the appropriate fee(s) is not enclosed, is unsigned, or is insufficient in amount, or any other mistake is made by Applicant which should incur additional fees, the Commissioner is authorized to charge Deposit Account No: __50-3748 (INGA,004/CIP) for the amount of any deficiency.

Respectfully submitted,

Malcolm Skolnick Reg. No. 33788

CytoGenix, Inc.

3100 Wilcrest Drive, Suite 140

when Stohned

Houston, Texas 77042 TEL: (713) 789-0070

FAX: (713) 789-0702

ATTORNEY FOR APPLICANT

Date: May 26, 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Application Number:	09/397,782
C	Filing Date:	September 16, 1999
1	First Named Inventor:	Charles CONRAD
	Art Unit:	1631
	Examiner Name:	James Martinell
Atto	rney Docket Number:	INGA, 004/CIP

Shage	of1
2 1006 W	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5840867	11/24/98	TOOLE, J.J., et al.	
	2	US-5910408	6/8/99	SZOSTAK, et al.	
					<u> </u>

FOREIGN PATENT DOCUMENTS

Examiner Cite Initials* No.	Foreign Patent Document Country Code- Number-Kind Code	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	3	MOHUCZY, D. et al., Antisense Inhibition of ATI Receptor in Vascular Smooth Muscle Cells Using Adeno- Associated Virus-Based Vector, Hypertension, pg 354-59, Part II, January 1999	

EXAMINER	DATE
SIGNATURE	CONSIDERED

Applicant's Copy

INFORMATION DISCLOSURE CITATION ATTY. DOC P.T.O. FORM 1449 ROOM IATA	
1 '\	s A. Conrad
10 1996 Billing DA	29. 1994
TRADEMAN	MPUE VED

U.S. PATENT DOCUMENTS

GROUP 1800

ENAMINER INITIAL	DOCUMENT NUMBER			OCUMENT NUMBER DATE NAME			CL.\SS		SUBCLASS	FILING DATE IF APPROPRIATE					
															2 //////
	11	1_	<u>L</u>	<u> </u>	<u> </u>										
	1	<u> </u>	$oxed{oldsymbol{oldsymbol{oldsymbol{eta}}}}$	$oxed{igspace}$	<u> </u>	Щ	 								
		╄		_	<u> </u>			<u> </u>		_ (
	$\perp \perp$	↓_	<u> </u>	$oxed{}$	<u> </u>					_					
	1	Ь.	<u></u>								Ī				

FOREIGN PATENT DOCUMENTS

100	נולאוו	:NT	NI.N	IBE:R	١.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
 		T								YES	NO	
									 		·	
\prod	1.								 			
17	T							· ·			_	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

4			Colvin, Richard A., et al., "Strucural Features of an RNA Containing the CUGGGA Loop of the Human Immunodesiciency Virus Type 1 Trans-Activation Response Element," Biochemistry 1993, 32, 1105-1112
4			Pollack, Jonathan R., et al., An RNA Stem-Loop Structure Directs Hepatitis B. Virus Genomic RNA Encapsidation." Journal of Virology 3254-3263 (June 1993)
4	·		D'Souza, D.J., et al. "Strong Binding of Single-stranded DNA by Stem-loop Oligonucleotides," Journal of Biomolecular Structure & Dynamics 10:141 (1992)
£~			Ohshima, A., et al. "In vivo duplication of genetic elements by the formation of stem-loop DNA without a RNA intermediate." Biochemistry 89:1016 (1992)
X-			Mead, D.A., et al. "A universal method for the direct cloning of PCR amplified nucleic acid," Biotechnology, Vol. 9:657 (1991)
<i>j'</i>			Xodo, L.E., ct al. DNA hairpin loops in solution. Correlation between primary structure, thermostability and reactivity with single-strand-specific nuclease from mung bean. Nucleic Acides Research 19:1505 (1991)
1	*		Barabino Silvia et al. Initsense probes targeted to an internal domain in 12 snRNP specifically inhibit the second step of pre-nRVL1 splicing." Nucleic Acids Research. Vol. 20, No. 17, 1157-1161 (1992)
1		les r	Nag. Dilip K. et al. "Seven-Base-Pair Inverted Repeats in DNA Form Stable Hairpins in Vivo in Saccharomyces cerevisiae." Genetics 129: 669-673 (November 1991)

7 1:A)



OTHER DOCUMENTS, Continued (Including Author, Title, Date, Pertinent Papers, Etc.)

,	Vickers. T., et al. "Inhibition of IIII'-LTR gene expression by oligonucleotides
X	targeted to the TAR element. "Nucleic Acides Research, Vol. 19, No. 12, 3359-3368 (1991)
,	Vicin 1 of 1 D 1
2	Victra. J., et al. Production of single-stranded plasmid DN.4." Methods Enzymol 153:3 (1987)
/	Baumann. U., et al. "Conformational analysis of hairpin
~~	oligodeoxyribonucleotides by a single-strand-specific nuclease." Fur 1
 	Biochem. 161:409 (1986)
	Peeters. B.P.H., et al. Plasmid pKUN9, a versatile ector for the selective
2	packaging of both DNA strands into single-stranded DNA-containing phage-like particles." Gene 41:39 (1986)
	Yanisch-Perron. C "Improved M13 phage cloning vectors and host strains:
1 2	Nucleotide sequences of the M13mp18 and pUC19 vectors," Gene 33:103
<u> </u>	(1985)
	Levinson. A., et al. "A finimal size plasmids containing and All3 origin for
2	production of single-strand transducing particles," J. Mol. Appl. Genet. 2:507
4	(1984)
1 / 1	Drew. Horace R., "Structural Specificities of Five Commonly Used DNA Nucleases." J. Mol. Biol. 176, 535-557 (1984)
	Dente, L., et al. pENBL: A new family of single stranded plasmids, "Nucleic
~	Acids Res. 11:1645 (1983)
2	Messing, J., et al. A new pair of M13 vectors for selecting either DNA strand of
2	double-digest restriction fragments, "Gene 19:269 (1982)
~	Beck. E., et al. "Nucleotide sequence and genome organization of filamentous
X X	hacteriophages fl and fd, "Gene 16:35 (1981)
d-	Dotto. Gian P., et al., "Functional Analysis of Bacteriophage fl Intergenic Region," Virology 114, 463-473 (1981)
	Cleary. J.M., et al. Replicating of the plasmid pBR322 under the control of a
1/2-	cloned replication origin from the single-stranded DNA phage M13." Proc.
2	Natl. Acad. Sci. 77:4638 (1980)
	Herrmann, R., et al. "Conversion of bacteriophage sd into an efficient single-
	stranded DNA vector system, "Mol. Gen. Genet. 177:231 (1980)
d d d L	Messing, J., "A multipurpose cloning system based on single-stranded DNA
	bacteriophage M13, "Recomb. DNA Tech. Bull. 2(2):43 (1979) Bcck. E., ct al. "Nucleotide sequence of bacteriophage fd DNA," Nucleic
2	Acids Res. 5:4495 (1978)
á	Konings. R.N.H et al. "Transcription of the filamentous phage genome." The
2	Single-stranded DNA phages (ed. D.T.Denhardt et al.), 507 (1978)
	Messing. J., et al. "Filamentous coliphage M13 as a cloning vehicle: Insertion
6	of a Hindll fragment of the lac regulatory region in M13 replicative form in
\	vitro: Proc. Natl. Acad. Sci., 74:3642 (1977)
EXAMINER	Marvin, D.A., Filamentous bacterial viruses, "Bacteriol, Rev. 33:172 (1969)
CAMMINER	DATE CONSIDERED
L	2 /1-1/46

PNAINER. Instal if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. In index-copy of this form with next communication to applicant (Middle) (Middl

est Harright



INFORMATION DISCLOSURE	CITATION
P.T.O. FORM 1449	

U.S. PATENT DOCUMENTS

INFORMATIO P.	N DISCLOSURE CITATION I.O. FORM 1449	ATTY. DOCKET NO.: INGA,004	SERIAL N	IO.: 09/169,79:	3	A _n
	(Page 1 of 3)	APPLICANT: Charles A. Conrad FILING DATE: October 9, 1998 GROUP: 1646				ECEL
						PECEIL OCT 25 2000
	. U.S	S. PATENT DOCUMENTS		•	ECH CEN	5.7000
EXAMINER INITIAL	DOCUMENT NUMBER DATE	E NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	"Top
J	5 8 0 8 0 3 6 9/15/19	998 Kool	536	24.3		
7	5 4 3 6 1 4 1 7/25/1	995 Miyata, et al.	435	91.1		•
2	5 3 2 0 9 5 8 6/14/1	994 Inouye, et al.	435	194		
2	5 3 1 2 7 2 8 5/17/1	994 Lizardi, et al.	435	6		
X	5 2 7 8 0 5 1 1/11/1	994 Seeman, et al.	435	91.52		
4	5 2 7 2 0 6 5 12/21/	Inouye, et al.	435	91.1!		
4-	5 2 1 5 8 9 9 6/1/1	993 Dattagupta	435	6		
2	5 2 0 8 1 4 9 5/4/1	993 Inouye '	435	91		
d_	5 1 9 0 9 3 1 3/2/1	993 Inouye	435	91		
2	5 1 6 2 2 0 9 11/10/	1992 Scheele	435	91	·	j
0	5 0 7 9 1 5 1 1/7/1	992 Lampson, et al.	435	91	ļ	
2	4 3 5 7 4 2 1 11/2/	1982 Eintage, et al.	435	68]

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER					BEF	\Box	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	LATION
		_	-					1		<u> </u>			YES	NO
7	WO	9	5	3	5	3.	6	9	28.12.1995	PCT- wo		· -]		<u> </u>
2	wo	9	4	2	3	0	2	6	03.10.1994	-PCT- No				*
<u></u>	wo	9	4	2	0	6	3	9	15.09.1994	PCT wo				
~	wo	9	4	1	3	6	8	9	23.06.1994	PCT wo				
40	wo	9	4	0	1	5	5	0	20.01.1994	PCT- wo				
de	GB	2	3	1	9	7	7	3	03,06.1998	UK				
oh		0	5	6	2	2	0	6	29.09.1993	Europe E?				
da		0	5	3	2	3	8	0	17.03.1993	Europe 62		_	<u> </u>	
×-		0	5	3	0	1	1	2	03.03.1993	Europe FP				1

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

13/01

73/01K

5/1/01 5/3/01 L 5/4/1 4 न्रंथी ~

2	Tanese, Naoko, et al. "Domain structure of the Moloney murine leukemia virus reverse transcriptase: Mutational analysis and separate expression of the DNA polymerase and RNase H activities, "Biochemistry," Vol. 85, pp. 1777-1781 - (1998). USF Proc. Nuft. Acad. Sci. USA-
de la	Mao, Jau-Ren, et al. "Gene regulation by antisense DNA produced in vivo," The Journal of Biological Chemistry, Vol. 270, No. 34, pp 19684-19687 (1995).
4	Crooke, Stanley T., et al. "Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes," Biochem. J., Vol. 312, pp. 599-608 (1995).
2	Marquet, R., et al. "tRNAs as primer of reverse transcriptases," Biochimie, Vol. 77, pp. 113-124 (1995).
d	Sands, Howard, et al. "Biodistribution and Metabolism of Internally 3H-Labeled Oligonucleotides. II. 3',5'-blocked Oligonucleotides," Molecular Pharmacology, Vol. 47, pp. 636-646 (1995).
~	Woolf, Tod M. "To Cleave or Not to Cleave: Ribozymes and Antisense," Antisense Research and Development, Vol. 5, pp. 227-232 (1995).

4 talls

5/3/01

Applicant's Copy

INFORMATION DISCLOSURE CLIATION P.T.O. FORM 1449	ATTY. DOCKET NO.: INGA,004	SEKIAL NO.: 09/169,793	
(Page 2 of 3)	APPLICANT: Charles A. Conrad		
·	FILING DATE: October 9, 1998	GROUP: 1646	- HED
			000

OTHER DOCUMENTS, Continued (Including Author, Title, Date, Pertinent Papers, Etc.)

	OTHER D	OCUMENTS, Continued (Including Author, Title, Date, Pertinent Papers, Etc.)
		TECH CE.
i	ţ	Willochiatelic No. Oleg, et al. Production of single-stranded DNA in
1		mammalian cells by means of a bacterial retron." The Journal of Biological
		Chemistry, Vol. 269, No. 4, pp 2380-2383 (1994).
~/		Inouye, Sumiko, et al. "The retron: a bacterial retroelement required for the
~		synthesis of msDNA." Current Biology, pp 713-718 (1993).
X-		Colvin, Richard A., et al. "Structural Features of an RNA Containing the
\sim	i	CUGGGA Loop of the Human Immunodeficiency Virus Type 1 Trans-Activation
		Response Element," Biochemistry, Vol. 32, No. 4, pp. 1105-1112 (1993).
		Pollack, Jonathan R., et al. "An RNA Stem-Loop Structure Directs Hepatitis B.
~	-	Virus Genomic RNA Encapsidation "Journal of Virus And Andrews Hepatitis B.
		Virus Genomic RNA Encapsidation," Journal of Virology, Vol. 67, pp. 3254-3263 (1993)
/		Silver, Jonathan, et al. "An RT-PCR assay for the enzyme activity of reverse
×_		transcriptase capable of detecting single virions," Nucleic Acids Research, Vol.
		21, No. 15, pp. 3593-3594 (1993).
/ /		D'Souza, D.J., et al. "Strong Binding of Single-stranded DNA by Stem-loop
V-		Oligonucleotides, Journal of Biomolecular Structure & Dynamics Vol 10
		pp. 141-151 (1992).
,		Gao, Wen-Yi, et al. "Phosphorothioate Oligonecleotides Are Inhibitors of
×_		Human DNA Polymerases and RNase H:Implications for Antisense
		Technology," Molecular Pharmacology, Vol. 41, pp. 223-229 (1992).
: ,	` ,	Ohshima, Atsushi, et al. "In Vivo Duplication of Genetic Elements by the
~		Formation of Stem-Loop DNA Without an RNA Intermediate," The Journal of
		Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 1016-1020 (1992).
		Bocklage, Hubertus, et al. "Cloning and characterization of the Mboll
\sim		restriction-modification system," Nucleic Acids Research, Vol. 19, No. 5,
	·	pp. 1007-1013 (1991).
		Nag, Dilip K., et al. "Seven-Base-Pair Inverted Repeats in DNA Form
\angle		Stable Hairpins in Vivo in Saccharomyces cerevisiae," Genetics, Vol. 129,
V —		pp. 669-673 (1991)
		Vickers T et al "Imbibiliar of UTI/ LTD
4		Vickers, T., et al. "Inhibition of HIV-LTR gene expression by oligonucleotides
\sim	·	targeted to the TAR element," Nucleic Acids Research, Vol. 19, No. 12, pp.
		3359-3368 (1991).
•		Xodo, L.E., et al. "DNA hairpin loops in solution. Correlation between
×	[primary structure, thermostability and reactivity with single-strand-specific
		nuclease from mung bean," Nucleic Acids Research, Vol. 19, No. 7,
		pp. 1505-1511 (1991).
	1	Tsurimoto, Toshiki, et al. "Replication Factors Required for SV40 DNA
2		Replication in Vitro," The Journal of Biological Chemistry, Vol. 266, No. 1.
		pp. 1950-1959 (1991).
,		Merchlinsky, Michael., "Resolution of Poxvirus Telomeres: Processing of
d.		Vaccinia Virus Concaterer Junctions by Conservative Strand Exchange."
		Journal of Virology, Vol. 64, No. 7, pp. 3437-3446 (1990).
. /		Manzini, Giorgio, et al. "Triple Helix Formation by Oligopurine-oligo-
<u>~</u>		pyrimidine DNA Fragments, J. Mol. Biol., Vol. 213, pp. 833-843 (1990).
		Alberts, Bruce, et al. Molecular Biology of The Cell (Garland Publishing,
<u>~</u>		New York, NY), pp. 255-257 (1989).
	4	: : : : : : • V+N, 1111, DU, 4227421117071

A fills 5/3/01

INFORMATION DISCLOSURE CLIATION P.T.O. FORM 1449	ATTY. DOCKET NO.: INGA,004	SEK.AL NO.: 09/169,793	
(Page 3 of 3)	APPLICANT: Charles A. Conrad		•
	FILING DATE: October 9, 1998	GROUP: 1646	RE

OTHER DOCUMENTS, Continued (Including Author, Title, Date, Pertinent Papers, Etc.)

	Maher, Louis J. III, et al. "Inhibition of DNA Binding Proteins by TECH CENTLE" Oligonucleotide-Directed Triple Helix Formation," Science, Vol. 245, pp.
2	1 /25-730 (1989).
	Chomczynski, Piotr, et al. "Single-Step Method of RNA Isolation by Acid
d d	Guanidinium Thiocyanate-Phenol-Chloroform Extraction," Analytical
	Biochemistry, Vol. 162, pp. 145-159 (1987). 156-159 (1987)
~	Vieira, Jeffrey, et al. "Production of single-stranded plasmid DNA,"
	Methods in Enzymology, Vol. 153, pp. 3-11 (1987).
j.	Nobile, Carlo, et al. "Stable Stem-Loop and Cruciform DNA Structures:
	Isolation of Mutants with Rearrangements of the Palindromic Sequence at the
×	Simian Virus 40 Replication Origin," Intervirology, Vol. 25, pp. 158-171 (1986).
~	Darnell, James E., et al. Molecular Cell Biology (Scientific American Books,
	Inc., New York, NY), pp. 438-440 (1986).
	Baumann, Ulrich, et al. "Conformational analysis of hairpin oligodeoxyribo- nucleotides by a single-strand-specific nuclease," Eur. J. Biochem., Vol. 161,
K	pp. 409-413 (1986).
X .	Kikuchi, Yo, et al. "Hairpin plasmid – a novel linear DNA of perfect hairpin
	structure," The FMBO Journal, Vol. 4, No. 7, pp. 1881-1886 (1985).
	Drew, Horace R. "Structural Specificities of Five Commonly Used DNA
	Nucleases, " J. Mol. Biol., Vol. 176, pp. 535-557 (1984).
	Land, Hartmut, et al. "5'-Terminal sequences of eucaryotic mRNA can be
6	cloned with high efficiency," Nucleic Acids Research, Vol. 9, No. 10, pp. 2251-
	2266 (1981).
4	Shinnick, Thomas M., et al. "Nucleotide sequence of Moloney murin leukaemia
	virus, "Nature, Vol. 293, pp. 543-548 (1981).
	Herrmann, Richard, et al. "Conversion of bacteriophage fd into an efficient
L	single-stranded DNA vector system," Mol. Gen. Genet. Vol. 177, pp. 231-242
	(1980).
~	Donis-Keller, Helen. "Site specific enzymatic cleavage of RNA," Nucleic Acids
	Research, Vol. 7, No. 1, pp. 179-192 (1979).
2	Beggs, Jean D. "Transformation of yeast by a replicating hybrid plasmid,"
	Nature, Vol. 275, pp. 104-109 (1978).
	Toulmé, Jean-Jacques, et al. "Selecting, preparing and handling antisense
	oligodeoxyribonucleotides," Source and date of publication unknown, pp. 39-74:
	ур. 37-14.
	·
EXAMINER	DATE CONSIDERED
1. 1.0 1.	5/3/01
- CFT	State Leave of 114-1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449 Patent and Trademark Office-U.S. Department of Commerce (Modified)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of _	2	

Application Number:	09/169,793
Filing Date:	Oct. 9, 1998
First Named Inventor:	Charles CONRAD
Art Unit:	1631
Examiner Name:	James Martinell
Attorney Docket Number:	INGA, 004

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5714323	02-1998	OHSHIMA, A., INOUYE, et al.	
	2	US-5756291	05-1998	GRIFFIN, et al.	
	3	US-5807718	09-1998	JOYCE, G.F. and BREAKER, R.R.	
	4	US-5503978	04-1999	SCHNEIDER, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code- Number-Kind Code	Publication date	Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, When Relevant Passages or Relevan Figures Appear	
	5	WO-9529993	11/9/95	NABEL, G.J., et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т²
	6	BARABINO, S., et al., Antisense probes targeted to an internal domain in U2 snRNP specifically inhibit the second step of pre-Nrma splicing, Nucleic Acids Research, 20 (17): 4457-4464, 1992	
	7	BECK, E., et al., Nucleotide sequence and genome organization of filamentous bacteriophages f1 and fd, Gene, 16: 35, 1981	
	8	BECK, E., et al., Nucleotide sequence of bacteriophage fd DNA, Nucleic Acids Res. 5: 4495, 1978	
	9	BENNETT, et al., Inhibition of Endotheleial Cell Adhesion Molecule Expression with Antisense Oligonucleotides, Journal of Immunology, 152: 3530-3540, 1994	
	10	BRANCH, A. Trends in Biochem. Sci., Vol 23, pgs 45-50 (1998)	
	11	CHAN, et al., Triplex DNA: Fundamentals, Advances, and Potential Applications for Gene Therapy, J. Mol. Med., 75: 267-282, 1997	
	12	CLACKSON, Controlling mammalian gene expression with small molecules, Current Opinion in Chemical Biology, 1: 210-218, 1997	
	13	CLEARY, J.M., et al., Replication of the plasmid pBR322 under the control of a cloned replication origin from the single-stranded DNA phage M13, PNAS, 77: 4638, 1980	
	14	CROOKE, S. Antisense Research and Application, Chapter 1, pgs 1-50, Ed. by S. Crook, Publ. by Springer-Verlag (1998)	
	15	DAUM, G., et al., The ins and outs of raf kinases, Trends in Biochemical Sciences, 19: 474-480, 1994	

EXAMINER	DATE
SIGNATURE	CONSIDERED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number:	09/169,793
Filing Date:	Oct. 9, 1998
First Named Inventor:	Charles CONRAD
Art Unit:	1631
Examiner Name:	James Martinell
Attorney Docket Number:	INGA, 004

		_	_	
Sheet	l	of	2	

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	16	DENTE, L., et al., pEMBL, A new family of single stranded plasmids, Nucleic Acids Res., 11: 1645, 1983
	17	DHUNDALE, A., et al., Structure of msDNA from Myxococcus xanthus: Evidence for a Long, self-Annealing RNA Precursor for the Covalently Linked, Branched RNA, Cell, 51: 1105-1112, Dec 1987
	18	DOTTO, G.P., et al., Functional Analysis of Bacteriophage f1 Intergenic Region, Virology, 114: 463-473, 1981
	19	FOSSE', P., et al., Modified Nucleotides of tRNA Pro Restrict Interactions in the Binary Primer/Template Complex of M-MuLV, J. Mol. Biol., 275: 731-746, 1998
	20	HELENE, C. and TOULME, J., Biochim. Biophys. Acta., 1049: 99-125, 1990
	21	KIM, K., et al., A Mutational Study of the Site-Specific Cleavage of EC83, a Multicopy Single-Stranded DNA (msDNA): Nucleotides at the msDNA Stem Are Important for Its Cleavage, Journal of Bacteriology, 179(20): 6518-6521, 1997
	22	KONINGS, R.N.H., et al., Transcription of the filamentous phage genome, The Single-stranded DNA phages (ed. D.T. Denhardt et al.), pp. 507, 1978
	23	LAMPSON, Bert C., et al., Reverse Transcriptase in a Clinical Strain of Escherichia coli: Production of Branched RNA-Linked msDNA, Research Articles, Science, 243: 1033-38, Feb 1989
	24	LEVINSON, A., et al., Minimal size plasmids containing and M13 origin for production of single-strand transducing particles, J. Mol. Appl. Genet 2: 507, 1984
	25	LIEBER, Andre, et al., Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library, Molecular and Cellular Biology, 15 (1): 540-551, Jan 1995
	26	LIMA, Tania M. and Lim, Dongbin, A Novel Retron That Produces RNA-less msDNA in Escherichia coli Using Reverse Transcriptase, Plasmid, 38: 25-33, June 1997
	27	MAO, Jau-Ren, et al., msDNA-Ec48, the smallest Multicopy Single-Stranded DNA from Escherichia coli, Journal of Bacteriology, 179 (24): 7865-7868, Dec 1997
	28	MARVIN, D.A., Filamentous bacterial viruses, Bacteriol. Rev., 33:172, 1969
	29	MEAD, D.A., et al., A universal method for the direct cloning of PCR amplified nucleic acid, Biotechnology, 9: 657, 1991
	30	MILLER, P.S., Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J.S. Cohen (ed.), CRC Press: Boca Raton, pp. 79, 1989
	31	MIYATA, S., et al., In vivo production of a stable single-stranded cDNA in Saccharomyces cerevisiae by means of a bacterial retron, PNAS, 89: 5735-5739 Biochemistry, July 1992
	32	NOONBERG, et al., In Vivo Generation of Highly Abundant Sequence-Specific Oligonucleotides for Antisense and Triplex Gene Regulation, Nucleic Acids Res., 22: 2830-2836, 1994
	33	PEETERS, B.P.H., et al., Plasmid pKUN9, a versatile ector for the selective packaging of both DNA strands into single-stranded DNA-containing phagelike particles, Gene 41: 39, 1986
	34	PETROPOULOS, C.J., Retroviral taxonomy, protein structure, sequences and genetic maps, J.M Coffin (Ed.), Retroviruses, 757-805, Appendix 2, New York: Cold Springs Harbor Press, 1997
	35	SANTORO, S.W. and Joyce, G. F., A general purpose RNA-cleaving DNA enzyme, PNAS, 94: 4262-4266, Biochemistry, April 1997
	36	SANTORO, S.W. and Joyce, G. F., Mechanism and Utility of an RNA-Cleaving DNA Enzyme, Biochemistry, 37 (38): 13330-13342, July 1998
	37	SEIDMAN, et al. Introduction of Plasmid DNA into Cells, in Current Protocols in Molecular Biology, Unit 1.8 (1997)
	38	YANISCH-PERRON, C., Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors, Gene 33: 103, 1985

EXAMINER	DATE
SIGNATURE	CONSIDERED

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
21144			

Application Number:	09/169,793
Filing Date:	Oct. 9, 1998
First Named Inventor:	Charles CONRAD
Art Unit:	1631 / 1633
Examiner Name:	James Martinell
Attorney Docket Number:	INGA, 004

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Cite Initials* No.	Foreign Patent Document Country Code- Number-Kind Code	Publication date	Nome of Patentee or Annheant of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		!		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	AGRAWAL, S., et al., Antisense Research and Application, Chapter 1, pg. 1-50, ed. S. Crooke, Springer-Verlag, 1998.	·
	2	BREAKER, R.R., In vitro Selection of Catalytic Polynucleotides, Chem. Rev., 97: 371-90, 1997	
			-

EXAMINER	DATE
SIGNATURE	CONSIDERED